Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab in Stage III Papillary Renal Cell Carcinoma
NCT06146777Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2023
- Primary completion
- Dec 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in papillary renal cell carcinoma (PRCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT06146777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06146777.